Open Orphan PLC CEO Appointment (6235C)
24 February 2022 - 6:00PM
UK Regulatory
TIDMORPH
RNS Number : 6235C
Open Orphan PLC
24 February 2022
24 February 2022
Open Orphan plc
("Open Orphan" or the "Company")
Appointment of Chief Executive Officer
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge
clinical trials, announces the appointment of Yamin 'Mo' Khan as
Chief Executive Officer of Open Orphan with immediate effect. Mo
joined the Board as a Non-Executive Director ("NED") in October
2021 and has worked closely with the team since then. Executive
Chairman, Cathal Friel will continue in his role under the new
management structure.
On 13 October 2021, the Company disclosed that Mo was appointed
as an Independent Non-Executive Director of Open Orphan and that he
would Chair both the Audit and Risk, and Nomination Committees.
With Mo stepping into an executive role, the Company will look to
fill the vacant Independent Non-Executive position and associated
committee positions within the next 6 months. In the interim Mo
will remain on both the Audit and Risk, and Nomination Committees
however he will step down as Chair with immediate effect. He will
also step down from the Remuneration Committee with immediate
effect. Elaine Sullivan, as Independent Non-Executive Director,
will take on the Chair position for the Audit & Risk Committee
in the interim and for the Nomination Committee on a full-time
basis.
Mo is a business leader and customer-focused CRO executive with
over 25 years of global clinical research experience across
clinical operations, project management, business development and
executive management functions. He previously worked at Pharm-Olam
International, a global CRO, for 19 years from 2000-2019. Mo worked
across a variety of senior positions including Executive Vice
President of Clinical Development and Global Director of Clinical
Operations. Mo was a key leader in driving the expansion and growth
of the company from a small niche Eastern European CRO to a global
player with offices across all continents. Laterally, he led global
business development at Pharm-Olam resulting in significant growth
and a successful sale in 2017, delivering substantial returns to
its shareholders. Prior to this he worked at Innovex and Quintiles
CRO (IQVIA).
Cathal Friel, Executive Chairman, Open Orphan, said: "We are
delighted to announce the appointment of Mo Khan as Chief Executive
Officer of Open Orphan. In the few short months since he joined us,
Mo has shared with us his invaluable experience and knowledge of
the CRO industry to the benefit of the Company. With substantial
growth across the global infectious and respiratory disease market,
the Company has experienced a significant increase in human
challenge study contract negotiations.
"The appointment of Mo as CEO adds considerable CRO experience
and expertise to our contract negotiations and will allow me to
focus my attention on other areas of the business to deliver
shareholder value and it is my intention to remain very hands on
and involved in the business as we go forward. I look forward to
working closely with Mo and the team in the weeks and months
ahead."
Yamin 'Mo' Khan, Chief Executive Officer, Open Orphan, said: "I
have been very impressed by the outstanding progress that Cathal,
the Board and the team have made in establishing Open Orphan as the
world leader in human challenge trials, with repeat business from
Big Pharma and consistent work from small to mid-sized
biotechnology companies. These are exciting times for Open Orphan
and its subsidiaries, and I look forward to working closely with
Cathal and the team as we go forward, helping to drive further
growth for the Company."
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Louisa Waddell
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson / Richard
Chambers
Davy (Euronext Growth Adviser and
Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Paul McManus / Sam Allen / Louis +44 (0)7980 541 893 / +44 (0) 7502 558
Ashe-Jepson 258 / +44 (0)
7747 515393
Notes to Editors
Open Orphan plc
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
contract research company that is a world leader in testing
vaccines and antivirals using human challenge clinical trials. The
Company provides services to Big Pharma, biotech, and
government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic and its state-of-the-art
24-bedroom QMB clinic with its highly specialised on-site virology
and immunology laboratory. The Company has a leading portfolio of
human challenge study models for infectious and respiratory
diseases and is developing a number of new models. There has been
significant growth of the infectious disease market, which is
estimated to grow to in excess of $250bn by 2025. The Group is
focused on refreshing its existing challenge models and develop new
models, such as Malaria, to address the dramatic growth potential
of the global infectious disease market.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological, and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma, and biotech companies.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing, and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCTJMRTMTTTBAT
(END) Dow Jones Newswires
February 24, 2022 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
